| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 11 | 2023 | 1366 | 1.380 |
Why?
|
| Adenocarcinoma | 8 | 2020 | 970 | 1.380 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 399 | 1.320 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 975 | 1.290 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 425 | 1.110 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2021 | 128 | 0.900 |
Why?
|
| Stomach Neoplasms | 3 | 2021 | 572 | 0.860 |
Why?
|
| Lymph Nodes | 5 | 2019 | 357 | 0.790 |
Why?
|
| Health Services for Transgender Persons | 1 | 2021 | 1 | 0.700 |
Why?
|
| Gender Identity | 1 | 2021 | 76 | 0.650 |
Why?
|
| Veterans | 7 | 2024 | 1756 | 0.650 |
Why?
|
| Patient Transfer | 1 | 2021 | 109 | 0.650 |
Why?
|
| Transgender Persons | 1 | 2021 | 66 | 0.640 |
Why?
|
| Natural Language Processing | 2 | 2024 | 76 | 0.630 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 387 | 0.620 |
Why?
|
| Fatigue | 1 | 2021 | 191 | 0.610 |
Why?
|
| Cancer Survivors | 2 | 2021 | 281 | 0.610 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 439 | 0.590 |
Why?
|
| Exercise Therapy | 1 | 2021 | 172 | 0.580 |
Why?
|
| Gastrectomy | 2 | 2021 | 104 | 0.580 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 236 | 0.580 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 1282 | 0.550 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 704 | 0.510 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1815 | 0.500 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 79 | 0.500 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 65 | 0.460 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 122 | 0.450 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 95 | 0.440 |
Why?
|
| Aged | 26 | 2024 | 20885 | 0.400 |
Why?
|
| Electronic Health Records | 3 | 2024 | 842 | 0.390 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1416 | 0.390 |
Why?
|
| Databases, Factual | 3 | 2018 | 1234 | 0.380 |
Why?
|
| Hospitals | 3 | 2020 | 434 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1324 | 0.340 |
Why?
|
| HIV Infections | 1 | 2023 | 2050 | 0.330 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 6771 | 0.320 |
Why?
|
| Middle Aged | 21 | 2024 | 28408 | 0.320 |
Why?
|
| Retrospective Studies | 16 | 2023 | 17634 | 0.310 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 149 | 0.300 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 1404 | 0.300 |
Why?
|
| Physician's Role | 1 | 2011 | 164 | 0.290 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 81 | 0.290 |
Why?
|
| Algorithms | 1 | 2016 | 1669 | 0.290 |
Why?
|
| Communication | 2 | 2022 | 540 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 1070 | 0.270 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1212 | 0.270 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 156 | 0.270 |
Why?
|
| Humans | 36 | 2024 | 130534 | 0.260 |
Why?
|
| Esophagectomy | 2 | 2018 | 70 | 0.260 |
Why?
|
| Male | 26 | 2024 | 64613 | 0.260 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 125 | 0.250 |
Why?
|
| Female | 24 | 2024 | 70545 | 0.230 |
Why?
|
| Primary Health Care | 1 | 2011 | 770 | 0.220 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 616 | 0.220 |
Why?
|
| United States | 12 | 2021 | 12002 | 0.210 |
Why?
|
| Neoplasms | 4 | 2024 | 2986 | 0.200 |
Why?
|
| Esophageal Neoplasms | 2 | 2018 | 384 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 262 | 0.190 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 902 | 0.180 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 84 | 0.180 |
Why?
|
| Adult | 11 | 2021 | 31114 | 0.170 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2016 | 400 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 747 | 0.170 |
Why?
|
| Frailty | 1 | 2024 | 140 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2019 | 12846 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 30 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 903 | 0.160 |
Why?
|
| Emotions | 2 | 2021 | 349 | 0.160 |
Why?
|
| Palliative Care | 2 | 2018 | 445 | 0.150 |
Why?
|
| False Negative Reactions | 1 | 2019 | 90 | 0.140 |
Why?
|
| Young Adult | 5 | 2021 | 10037 | 0.140 |
Why?
|
| Comorbidity | 3 | 2019 | 1589 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 273 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1122 | 0.140 |
Why?
|
| Hospice Care | 1 | 2018 | 31 | 0.130 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 22 | 0.130 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 15 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 102 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 103 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 31 | 0.130 |
Why?
|
| Stomach | 1 | 2019 | 270 | 0.120 |
Why?
|
| Veterans Health | 1 | 2018 | 170 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2019 | 358 | 0.120 |
Why?
|
| Pancreatectomy | 1 | 2017 | 147 | 0.120 |
Why?
|
| Cohort Studies | 7 | 2021 | 5049 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 144 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 125 | 0.120 |
Why?
|
| Motor Activity | 1 | 2019 | 489 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 134 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 1208 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 525 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 127 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 911 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 238 | 0.110 |
Why?
|
| Adolescent | 5 | 2021 | 20889 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 787 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 337 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 356 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 718 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 263 | 0.100 |
Why?
|
| Registries | 2 | 2019 | 1614 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2017 | 1481 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2290 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 224 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 477 | 0.090 |
Why?
|
| Hospitalization | 1 | 2021 | 1942 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2017 | 760 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2013 | 565 | 0.080 |
Why?
|
| Quinazolines | 1 | 2012 | 176 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1265 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 978 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 739 | 0.080 |
Why?
|
| Outpatients | 1 | 2013 | 262 | 0.080 |
Why?
|
| Quality of Life | 1 | 2021 | 2072 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2080 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2011 | 61 | 0.080 |
Why?
|
| Piperidines | 1 | 2012 | 221 | 0.080 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 100 | 0.080 |
Why?
|
| Survival Rate | 3 | 2021 | 2110 | 0.080 |
Why?
|
| Perception | 1 | 2011 | 228 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 243 | 0.070 |
Why?
|
| Gait | 2 | 2021 | 141 | 0.070 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 335 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1546 | 0.070 |
Why?
|
| Inpatients | 1 | 2013 | 561 | 0.070 |
Why?
|
| Prognosis | 1 | 2018 | 4866 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2008 | 26 | 0.070 |
Why?
|
| Attitude to Death | 1 | 2008 | 39 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2011 | 719 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2011 | 559 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2008 | 246 | 0.060 |
Why?
|
| Fear | 2 | 2021 | 190 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1800 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 4058 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1579 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 532 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2012 | 4664 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1376 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 112 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2413 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2596 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2018 | 3685 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1440 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 2822 | 0.030 |
Why?
|
| Attention | 1 | 2019 | 191 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2019 | 191 | 0.030 |
Why?
|
| Exercise | 1 | 2024 | 891 | 0.030 |
Why?
|
| Postural Balance | 1 | 2019 | 133 | 0.030 |
Why?
|
| Diplopia | 1 | 2017 | 45 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 270 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 133 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 158 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 355 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 159 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 953 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 23 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 125 | 0.030 |
Why?
|
| Health Services | 1 | 2016 | 69 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 630 | 0.030 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 62 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1116 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 3367 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 11013 | 0.020 |
Why?
|
| Independent Living | 1 | 2013 | 64 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 148 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3353 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 367 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 185 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 715 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2012 | 285 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3038 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 421 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 324 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 673 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 324 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2013 | 381 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6175 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 992 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1796 | 0.020 |
Why?
|
| Existentialism | 1 | 2008 | 3 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 13 | 0.020 |
Why?
|
| Grief | 1 | 2008 | 21 | 0.020 |
Why?
|
| New York | 1 | 2008 | 69 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 724 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 49 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 2692 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 618 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1263 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2195 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1363 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 179 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5187 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 223 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 647 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 386 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 888 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1221 | 0.010 |
Why?
|
| Family | 1 | 2008 | 587 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 2016 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6424 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 33726 | 0.010 |
Why?
|